WORCESTER, Mass., July 8, 2008 (PRIME NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT) (www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, has initiated dosing of over one hundred patients in the Company’s pivotal Phase III clinical trial of Generex Oral-lyn(tm), its flagship proprietary oral insulin spray product. Dosing of patients is now underway at 31 clinical trial sites in the United States, Canada, Russia, and Ukraine.
